News
LABT
0.4895
+5.04%
0.0235
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
Lakewood-Amedex Biotherapeutics Presents Research Highlighting Antimicrobial Profile Of Nu-3, Lead Clinical Candidate, At IDWeek 2026; Topline Data From Trial Expected In Q1 2027
Benzinga · 1d ago
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
PR Newswire · 1d ago
Weekly Report: what happened at LABT last week (1012-1016)?
Weekly Report · 3d ago
Weekly Report: what happened at LABT last week (1005-1009)?
Weekly Report · 10/12 10:38
Lakewood-Amedex announces preclinical data from Bisphosphocin studies
TipRanks · 10/07 12:10
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/07 12:05
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
PR Newswire · 10/07 12:02
Weekly Report: what happened at LABT last week (0928-1002)?
Weekly Report · 10/05 10:37
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
PR Newswire · 10/01 12:02
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 09/28 17:06
Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up 20% Today?
TipRanks · 09/28 13:47
Lakewood-Amedex Biotherapeutics reports positive MIC data from Nu-3 study
TipRanks · 09/28 12:11
Lakewood-Amedex Biotherapeutics Announces Minimum Inhibitory Concentration Data From Recent Clinical Isolates Of Nu-3 Demonstrates Consistent Activity Against All Organisms
Benzinga · 09/28 12:09
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 09/28 12:05
Weekly Report: what happened at LABT last week (0921-0925)?
Weekly Report · 09/28 10:32
Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
Benzinga · 09/24 14:50
Lakewood-Amedex Biotherapeutics: First patient dosed in Phase2a trial of Nu-3
TipRanks · 09/24 12:11
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 09/21 12:06
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter to Shareholders
Benzinga · 09/21 12:06
More
Webull provides a variety of real-time LABT stock news. You can receive the latest news about Lakewood-Amedex through multiple platforms. This information may help you make smarter investment decisions.
About LABT
Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.